Alterations of gut microbiota and its correlation with the liver metabolome in the process of ameliorating Parkinson's disease with Buyang Huanwu decoction

Hu, Jianran; Li, Ping; Zhao, Hongmei; Ji, Pengyu; Yang, Yong; Jun, Ma; Zhao, Xin

doi:10.1016/j.jep.2023.116893

Cited by 4 publications

(6 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Association with Non-motor Symptoms: Non-motor symptoms, including depression and anxiety, significantly detract from the quality of life for individuals with PD and often manifest prior to the disease's motor symptoms. This timing suggests a potential connection to early pathological changes within PD (13,18,20,21,24,26,28,31,33,34,36,39,42,43,45,47,50,51,53,55,58,59,61). The gut-brain axis mediates the gut microbiota's effect on mood and behavior, with specific bacterial strains producing neurotransmitters like serotonin and dopamine, crucial for mood regulation (9,13,16,18,20,22,25,27,30,32,35,37,43,45,50,52,56,58).…”

Section: Behavioral and Cognitive Effects Of Gut Microbiota In Pdmentioning

confidence: 96%

“…These metabolites possess the ability to traverse the blood–brain barrier, modulating brain functions including neural activity, neuroinflammation, and neuroprotection ( 22 , 23 , 26 , 27 , 29 , 31–37 , 39 , 42 , 43 , 45 , 46 , 48 , 51–53 , 55 , 57–60 ). In PD, alterations in the production of gut microbiota-derived metabolites may compromise neuronal health and foster neurodegeneration ( 19 , 20 , 22 , 24–26 , 28 , 30–32 , 35–44 , 46–54 , 56–61 ). The microbiota’s capacity to regulate the secretion of gut hormones such as ghrelin and glucagon-like peptide-1 (GLP-1), both noted for their neuroprotective properties, may also be pivotal in modulating PD’s progression ( 23 , 27 , 31 , 33 , 35 , 39 , 53 ).…”

Section: Mechanisms Of Gut Microbiota Influence On Pdmentioning

confidence: 99%

“…Certain gut bacteria have the ability to metabolize levodopa, the cornerstone treatment for PD, thereby influencing its bioavailability and therapeutic impact ( 23 , 25 , 27–29 , 31–33 , 35–37 , 39 , 42 , 44 , 46 , 49–51 , 53–61 ). Conversely, PD medications might alter the gut microbiota’s composition, influencing the disease’s trajectory and gastrointestinal manifestations ( 20 , 22 , 24 , 26 , 30 , 34 , 38 , 40 , 41 , 43 , 45 , 47 , 48 , 52 ). Appreciating this reciprocal relationship is essential for refining PD management strategies, suggesting that gut microbiota modulation could amplify medication efficacy and minimize negative side effects ( 20–61 ).…”

Section: Gut Microbiota In Pd Treatmentmentioning

confidence: 99%

“…Cognitive impacts and PD-related dementia : Cognitive impairment, including dementia, poses a significant challenge in PD, potentially progressing as the disease advances ( 14 , 15 , 17 , 23 , 30 , 41 , 44 , 48 , 52 ). The gut microbiota’s role in cognitive health is increasingly acknowledged, with evidence suggesting that dysbiosis may underlie the cognitive decline observed in PD ( 3 , 4 , 7 , 8 , 11 , 12 , 16 , 18 , 20 , 24 , 26 , 27 , 29 , 31 , 33 , 35 , 37 , 39 , 42 , 43 , 45 , 47 , 49 , 50 , 53 , 55 , 57 , 60 ). Certain bacteria influence the levels of amyloid and tau proteins, associated with neurodegenerative conditions such as Alzheimer’s disease and PD-related dementia ( 9 , 19 , 22 , 28 , 34 , 38 , 46 , 51 , 54 , 58 , 61 ).…”

Section: Behavioral and Cognitive Effects Of Gut Microbiota In Pdmentioning

confidence: 99%

See 3 more Smart Citations

The interplay between gut microbiota and the brain-gut axis in Parkinson’s disease treatment

Jia,

Wang,

Liu

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

This study delves into the pivotal role of the gut microbiota and the brain-gut axis in Parkinson’s Disease (PD), a neurodegenerative disorder with significant motor and non-motor implications. It posits that disruptions in gut microbiota—dysbiosis—and alterations in the brain-gut axis contribute to PD’s pathogenesis. Our findings highlight the potential of the gastrointestinal system’s early involvement in PD, suggested by the precedence of gastrointestinal symptoms before motor symptoms emerge. This observation implies a possible gut-originated disease pathway. The analysis demonstrates that dysbiosis in PD patients leads to increased intestinal permeability and systemic inflammation, which in turn exacerbates neuroinflammation and neurodegeneration. Such insights into the interaction between gut microbiota and the brain-gut axis not only elucidate PD’s underlying mechanisms but also pave the way for novel therapeutic interventions. We propose targeted treatment strategies, including dietary modifications and fecal microbiota transplantation, aimed at modulating the gut microbiota. These approaches hold promise for augmenting current PD treatment modalities by alleviating both motor and non-motor symptoms, thereby potentially improving patient quality of life. This research underscores the significance of the gut microbiota in the progression and treatment of PD, advocating for an integrated, multidisciplinary approach to develop personalized, efficacious management strategies for PD patients, combining insights from neurology, microbiology, and nutritional science.

show abstract

Section: Behavioral and Cognitive Effects Of Gut Microbiota In Pdmentioning

confidence: 96%

Section: Mechanisms Of Gut Microbiota Influence On Pdmentioning

confidence: 99%

Section: Gut Microbiota In Pd Treatmentmentioning

confidence: 99%

Section: Behavioral and Cognitive Effects Of Gut Microbiota In Pdmentioning

confidence: 99%

See 2 more Smart Citations

The interplay between gut microbiota and the brain-gut axis in Parkinson’s disease treatment

Jia,

Wang,

Liu

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…Recent studies propose that the liver impacts the risk and progression of neurodegenerative disorders [ 16 , 17 , 18 , 19 ]. As the peripheral organs and the central nervous system (CNS) bidirectionally communicate, changes in one can influence the other.…”

Section: Introductionmentioning

confidence: 99%

Intravenous MSC-Treatment Improves Impaired Brain Functions in the R6/2 Mouse Model of Huntington’s Disease via Recovered Hepatic Pathological Changes

Yu-Taeger,

El-Ayoubi,

et al. 2024

Cells

View full text Add to dashboard Cite

Huntington’s disease (HD), a congenital neurodegenerative disorder, extends its pathological damages beyond the nervous system. The systematic manifestation of HD has been extensively described in numerous studies, including dysfunction in peripheral organs and peripheral inflammation. Gut dysbiosis and the gut–liver–brain axis have garnered greater emphasis in neurodegenerative research, and increased plasma levels of pro-inflammatory cytokines have been identified in HD patients and various in vivo models, correlating with disease progression. In the present study, we investigated hepatic pathological markers in the liver of R6/2 mice which convey exon 1 of the human mutant huntingtin gene. Furthermore, we evaluated the impact of intravenously administered Mesenchymal Stromal Cells (MSCs) on the liver enzymes, changes in hepatic inflammatory markers, as well as brain pathology and behavioral deficits in R6/2 mice. Our results revealed altered enzyme expression and increased levels of inflammatory mediators in the liver of R6/2 mice, which were significantly attenuated in the MSC-treated R6/2 mice. Remarkably, neuronal pathology and altered motor activities in the MSC-treated R6/2 mice were significantly ameliorated, despite the absence of MSCs in the postmortem brain. Our data highlight the importance of hepatic pathological changes in HD, providing a potential therapeutic approach. Moreover, the data open new perspectives for the search in blood biomarkers correlating with liver pathology in HD.

show abstract

Progress of Exosomal MicroRNAs and Traditional Chinese Medicine Monomers in Neurodegenerative Diseases

Liang,

Zhu,

Liu

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

Exosomes, extracellular vesicles secreted by various cells, actively participate in intercellular communication by facilitating the exchange of crucial molecular information such as DNA, RNA, and lipids. Within this intricate network, microRNAs, endogenous non‐coding small RNAs, emerge as pivotal regulators of post‐transcriptional gene expression, significantly influencing the development of neurodegenerative diseases. The historical prominence of traditional Chinese medicine (TCM) in clinical practice in China underscores its enduring significance. Notably, TCM monomers, serving as active constituents within herbal medicine, assume a critical role in the treatment of neurodegenerative diseases, particularly in mitigating oxidative stress, inhibiting apoptosis, and reducing inflammation. This comprehensive review aims to delineate the specific involvement of exosomal microRNAs in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, and amyotrophic lateral sclerosis. Furthermore, the exploration extends to the application of TCM monomers, elucidating their efficacy as therapeutic agents in these conditions. Additionally, the review examines the utilization of exosomes as drug delivery carriers in the context of neurodegenerative diseases, providing a nuanced understanding of the potential synergies between TCM and modern therapeutic approaches. This synthesis of knowledge aims to contribute to the advancement of our comprehension of the intricate molecular mechanisms underlying neurodegeneration and the potential therapeutic avenues offered by TCcom interventions.

show abstract

Alterations of gut microbiota and its correlation with the liver metabolome in the process of ameliorating Parkinson's disease with Buyang Huanwu decoction

Cited by 4 publications

References 76 publications

The interplay between gut microbiota and the brain-gut axis in Parkinson’s disease treatment

The interplay between gut microbiota and the brain-gut axis in Parkinson’s disease treatment

Intravenous MSC-Treatment Improves Impaired Brain Functions in the R6/2 Mouse Model of Huntington’s Disease via Recovered Hepatic Pathological Changes

Progress of Exosomal MicroRNAs and Traditional Chinese Medicine Monomers in Neurodegenerative Diseases

Contact Info

Product

Resources

About